AASLD Liver Meeting | Conference

Dr. Jordi Bruix on Efficacy and Safety of Regorafenib in HCC After Sorafenib

November 17th 2016

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the efficacy, safety, and quality-of-life with regorafenib, a novel second-line agent that is currently being considered for approval by the FDA for second-line systemic therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib.

Dr. Ghassan Abou-Alfa on Impact of Second-Line Regorafenib in HCC

November 17th 2016

​Ghassan K. Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the impact of the phase III RESORCE trial, which demonstrated that regorafenib improved survival over placebo for patients with hepatocellular carcinoma (HCC) that progressed on sorafenib.

Tumor Burden Limits Liver Transplant Feasibility for HCC

November 17th 2016

Researchers have uncovered an upper limit in tumor burden after which there is a lower probability of successfully downstaging patients with hepatocellular carcinoma for liver transplantation.

Multidisciplinary Care Associated With Improved OS for HCC Patients

November 15th 2016

Multidisciplinary tumor boards led to higher utilization of guideline-recommended curative therapies, which was associated with improved overall survival for patients with early-stage hepatocellular carcinoma.

Dr. Montano-Loza on Link Between HCC Risk and High Visceral Adipose Tissue

November 15th 2016

Aldo J. Montano-Loza, MD, MSc, PhD, associate professor of medicine, program director of hepatology, gastroenterology rotation supervisor, University of Alberta, discusses the link between high visceral adipose tissue and hepatocellular carcinoma risk in patients with cirrhosis.

DAAs Not Associated With Increased HCC Risk in HCV Patients

November 15th 2016

Treatment with direct-acting antiviral therapy did not increase the risk of developing hepatocellular carcinoma in patients with hepatitis C virus (HCV) infection.

Researchers Validate Novel Prediction Index for HCC After Liver Transplant

November 15th 2016

A new system for gauging the probability for hepatocellular carcinoma recurrence following liver transplant surgery has proved successful.

Dr. Naveed Zafar Janjua on Impact of Hepatitis C Treatment Timing on HCC Risk

November 15th 2016

Naveed Zafar Janjua, MBBS, MSc, DrPH, senior scientist, clinical prevention services, BC Centre for Disease Control and clinical associate professor, School of Population and Public Health, University of British Columbia, discusses the findings from the British Columbia hepatitis testers cohort, which looked at the impact of hepatitis infection on long term risk of hepatocellular carcinoma (HCC).

Regorafenib Renews Hope in Hepatocellular Carcinoma

November 14th 2016

There has been renewed optimism in hepatocellular carcinoma with regorafenib, a novel second-line agent that is currently being considered for approval by the FDA.

Preclinical Studies Help to Illuminate Immunotherapy's Role in HCC

November 14th 2016

Following on their impressive success in the treatment of several other tumor types, immune-based therapies are being studied in clinical trials for hepatocellular carcinoma and are showing promising signals of efficacy.

x